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Abstract Antineutrophil cytoplasmic autoantibodies (ANCAs)
directed to proteinase 3 (PR3-ANCA) or myeloperoxidase
(MPO-ANCA) are strongly associated with the ANCA-
associated vasculitides—Wegener’s granulomatosis, micro-
scopic polyangiitis, and Churg-Strauss syndrome. Clinical
observations, including the efficacy of B-cell depletion via
rituximab treatment, support—but do not prove—ap a t h o -
genic role for ANCA in the ANCA-associated vasculitides.
In vitro experimental studies show that the interplay of
ANCA, neutrophils, the alternative pathway of the comple-
ment system, and endothelial cells could result in lysis of
the endothelium. A pathogenic role for MPO-ANCA is
strongly supported by in vivo experimental studies in mice
and rats, which also elucidate the pathogenic mechanisms
involved in lesion development. Unfortunately, an animal
model for PR3-ANCA–associated Wegener’sg r a n u l o m a t o -
sis is not yet available. Here, cellular immunity appears to
play a major role as well, particularly via interleukin-17–
producing T cells, in line with granulomatous inflammation
in the lesions. Finally, microbial factors, in particular
Staphylococcus aureus and gram-negative bacteria, seem to
be involved in disease induction and expression, but further
studies are needed to define their precise role in disease
development.
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Introduction
The antineutrophil cytoplasmic autoantibody (ANCA)-
associated vasculitides (AAVs) include Wegener’s granulo-
matosis (WG); microscopic polyangiitis and its renal
limited form, idiopathic necrotizing crescentic glomerulo-
nephritis; and Churg-Strauss syndrome (CSS) [1]. These
small vessel vasculitides are characterized by necrotizing
inflammation of the vessel wall, particularly of small
arteries, arterioles, capillaries, and venules, in conjunction
with the presence of ANCAs. ANCAs in the AAV are
directed to proteinase 3 (PR3) or to myeloperoxidase
(MPO). In the right clinical context, sensitivity and
specificity of PR3-ANCA and MPO-ANCA for the AAVs
are extremely high, with the possible exception of CSS [1].
In CSS, however, a primarily vasculitic disease pattern is
strongly associated with MPO-ANCA, whereas a disease
presentation dominated by eosinophilic tissue infiltration
generally is ANCA negative [2]. The strong association of
PR3-ANCA/MPO-ANCA with the AAVs has led to the
assumption that ANCAs are directly involved in the
pathogenesis of these diseases.
In this review, I discuss current evidence indicating that
ANCAs are involved in the pathogenesis of AAV. Data
from clinical studies and from in vitro and in vivo
experimental studies are presented. These data will provide
insight into the pathophysiologic pathways involved in
lesion development of the AAVs. Insight in these pathways
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of treatment.
Are ANCAs Pathogenic?
Evidence from Clinical Observations
As mentioned, PR3-ANCA and MPO-ANCA are strongly
associated with AAVs. Furthermore, longitudinal observa-
tions showed a relationship between increases in levels of
PR3-ANCA and the occurrence of relapses. In a study of
100 patients with WG and PR3-ANCA, Boomsma et al. [3]
observed that 26 of the 33 relapses that occurred during the
study period were preceded by a rise in PR3-ANCA as
measured by enzyme-linked immunosorbent assay (sensi-
tivity, 79%), whereas 12 of 38 increases were not followed
by a relapse (specificity, 68%). Although the association
between increases in ANCA and ensuing relapses in
patients with AAVs has been confirmed by others, Finkiel-
man et al. [4], using data from the Wegener’s Granuloma-
tosis Etanercept Trial [5], could not confirm this
association. In their study, the increase in ANCA levels
was not associated with a relapse, and the decrease in
ANCA following induction treatment was not associated
with a shorter time to remission, although titers of ANCA
were significantly lower at the time of remission compared
with titers at disease onset. A clinical argument for a
pathogenic role of PR3-ANCA comes otherwise from
observations that the persistence of ANCA after induction
of remission in patients with WG is strongly associated
with relapses. Stegeman et al. [6] showed that persistence
of ANCA confers a relative risk of 9.0 for relapse. These
findings, confirmed by others, have led to the question of
whether maintenance treatment for AAVs should be
continued for a longer period when ANCAs persist after
induction of remission [7]. A randomized controlled trial to
assess this issue is currently under way. Another argument
for a pathogenic role of ANCAs in AAVs comes from two
recently published papers describing the efficacy of
rituximab, a B-cell–depleting monoclonal antibody, in
patients with severe, active AAVs. The Rituximab for
ANCA-Associated Vasculitis study showed that rituximab
was not inferior to daily cyclophosphamide treatment for
induction of remission in severe AAVs and may be superior
in relapsing disease [8￿]. The second study also showed the
efficacy of rituximab as not being inferior to that of
intravenous cyclophosphamide in severe AAVs with
impending renal insufficiency [9￿]. Although the effects of
B-cell depletion may be more extensive than inhibiting
antibody production, the efficacy of rituximab in AAV
could be explained at least in part by its effect on ANCA
production.
Finally, one clinical observation strongly suggests a
pathogenic role for MPO-ANCA. Bansal and Tobin [10]
reported a case of neonatal microscopic polyangiitis in a
child born to a mother with MPO-ANCA. Taken together,
current evidence from clinical studies suggests, but certain-
ly does not prove, that ANCAs are involved in the
pathogenesis of AAVs.
Evidence from In Vitro Experiments
A major breakthrough regarding the pathogenicity of
ANCA was based on the discovery by Falk et al. [11] that
ANCAs can activate primed neutrophils for the production
of reactive oxygen species and the release of lytic enzymes.
This process of activation occurs on a surface only, Fcγ
receptors (in particular, FcγRIIa and FcγRIIb) are in-
volved, and the signal transduction routes involved in
activation have been largely delineated [12]. These in vitro
data could open new possibilities for more focused treatment
of AAVs. For instance, Schreiber et al. [13￿] showed in vitro
that phosphoinositol 3-kinase–γ mediates ANCA-induced
degranulation and granulocyte-macrophage colony-
stimulating factor stimulated migration in a transwell assay
of isolated human neutrophils; a specific inhibitor of this
enzyme abrogated these processes in vitro and protected
mice against the development of necrotizing glomerulone-
phritis in a murine model of MPO-ANCA–associated
glomerulonephritis.
In vitro data also demonstrate the role of complement in
AAVs as an amplification loop for ANCA-induced neutrophil
activation.Schreiberetal.[14￿] also showed that supernatants
from ANCA-activated neutrophils activate the complement
system via the alternative pathway, resulting in the produc-
tion, among others, of C5a. C5a was able to prime
neutrophils for ANCA-induced activation, and blocking of
the C5a receptor on neutrophils abrogated this process. The
important role of complement in AAVs also has been pointed
out in animal models of AAV, as discussed subsequently. In
agreement with these experimental data, the complement
components membrane attack complex, C3d, and factor B
could be detected in diseased glomeruli of patients with
AAVs. The alternative pathway component factor B colo-
calized with membrane attack complex, but the classical
pathway component C4d could not be detected [15].
Necrotizing vasculitis in AAVs is characterized by
neutrophil activation within the vessel wall requiring
neutrophil endothelial interaction. In vitro studies have
shown that ANCAs stimulate neutrophil-induced cytotox-
icity toward endothelial cells [16]. In an in vitro flow
system, Radford et al. [17] demonstrated that ANCAs
induce conversion of rolling of neutrophils to firm integrin-
mediated adhesion. Adhesion could be blocked by inhibit-
ing monoclonal antibodies to the FcγRIIa receptor and to
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intravital microscopy that MPO-ANCAs reduce leukocyte
rolling over the endothelium and augment adhesion to and
transmigration across the endothelium, a process that can be
inhibited by blocking Fcγ receptors and β2 integrins [18].
One particular observation of note was made by Kessen-
brock et al. [19￿]. They showed that neutrophil activation
by ANCA induces the generation of neutrophil extracellular
traps (NETs), which contain PR3 and MPO. NETs can
adhere to the endothelium and damage these cells.
Furthermore, they can activate plasmacytoid dendritic cells,
thus contributing to local production of ANCAs at the site
of inflammation.
In conclusion, in vitro studies strongly support a
pathogenic role for ANCAs in AAVs. The adaptive immune
response manifested by ANCAs interacts with innate
immunity, in particular neutrophils and the complement
system. Together they target the endothelium, resulting in
necrotizing vasculitis.
Evidence from In Vivo Experiments
The most convincing evidence for a pathogenic role of
ANCA comes from in vivo experimental studies. After
immunizing MPO-deficient mice with murine MPO, Xiao
et al. [20] observed that the mice developed antibodies to
murine MPO. Next, spleen cells from these immunized
mice were transferred into immunodeficient or healthy
mice. The recipients developed pauci-immune necrotizing
crescentic glomerulonephritis (NCGN) and hemorrhagic
pulmonary capillaritis. When they transferred only IgG
from the immunized mice, the recipient mice developed
pauci-immune focal NCGN, demonstrating the pathogenic-
ity of MPO-ANCA. Addition of lipopolysaccharide to the
IgG fraction augmented the lesions, and lesion development
could be blocked in part by anti–tumor necrosis factor
treatment [21]. Neutrophils are required for lesion devel-
opment, as shown by neutrophil depletion [22]. Within
neutrophils, the presence of MPO is essential, as shown by
Schreiber et al. [23]. When MPO
−/− bone marrow was
transferred into irradiated MPO
+/+ mice, lesions did not
develop. Conversely, transfer of MPO
+/+ bone marrow cells
into MPO
−/− mice with anti-MPO antibodies resulted in
NCGN. Besides neutrophils, the complement system
proved essential to lesion development. Complement
depletion prevented disease development, and mice defi-
cient in C5 or complement factor B did not demonstrate
NCGN. Absence of complement factor C4, however, did
not influence NCGN development [24]. These data show
that activation of the complement system via the alternative
pathway occurs in this animal model of MPO-ANCA–
associated AAV. Indeed, blocking of C5a or the C5a
receptor could prevent the development of vasculitis in this
murine model [14￿]. This opens new methods of treatment.
Another method of treatment is suggested by recent
experiments in which endoglycosidase S (Endo S) was
used to modulate IgG glycosylation, thus abolishing Fc
receptor–mediated activation of leukocytes and comple-
ment. Administration of Endo-S–treated anti-MPO anti-
bodies to recipient mice strongly reduced neutrophil influx
and crescent formation in the above-described model of
MPO-ANCA AAV [25￿]. The pathogenic potential of
MPO-ANCA also was demonstrated in a rat model in
which rats were immunized with human MPO [26].
Through use of intravital microscopy, the ability of MPO-
ANCA to enhance leukocyte-endothelial interaction and to
induce microvascular hemorrhage was demonstrated.
Whereas the aforementioned experimental studies
strongly suggest or even prove that MPO-ANCAs are
pathogenic in the AAVs, the in vivo evidence of a
pathogenic role of PR3-ANCA is less clear. To establish
an animal model for PR3-ANCA AAV, Pfister et al. [27]
used the same approach as described above for a murine
model of MPO-ANCA AAV. They immunized PR3-
deficient mice with recombinant murine PR3. These mice
developed anti-PR3 antibodies that recognized murine PR3
on the membrane of murine neutrophils. Next, the anti-
bodies were passively transferred into naive mice. No signs
of vasculitis developed in the kidneys or lungs. The only
observation that they made was of an increased tumor
necrosis factor–α–induced local inflammation in the skin of
anti-PR3 transferred mice compared with control mice.
Also, a rat model of PR3-ANCA AAV was not successful.
Van der Geld et al. [28] immunized rats with human–mouse
chimeric PR3. These rats developed antibodies that reacted
with recombinant rat PR3 and selectively bound to rat
granulocytes, but vasculitic lesions did not develop despite
systemic administration of lipopolysaccharide. Why these
efforts to establish an animal model of PR3-ANCA AAV
have not been successful is currently not clear. As discussed
subsequently, increasing evidence indicates that in addition
to autoantibodies, effector T cells are involved in the
pathogenesis of PR3-ANCA–associated WG. As WG is
closely associated with PR3-ANCA, this may explain why
autoantibodies alone are not sufficient to induce the clinical
phenotype of PR3-ANCA–associated vasculitis.
Two other models related to AAV need attention. The
first relates to the possibility that a protein complementary
to PR3 may induce PR3-ANCA. A complementary protein
is a protein translated from the antisense DNA strand
encoding for the original protein. Pendergraft et al. [29]
observed that some patients with PR3-ANCA AAV had
antibodies to complementary PR3 (cPR3). Next, they
immunized mice with cPR3 and found that these mice not
only developed antibodies to cPR3, but also to PR3. As a
complementary protein seems to be a mirror of the original
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induce an antibody response to PR3 via idiotypic–anti-
idiotypic interaction. Interestingly, they noticed that cPR3
shows homology with several microbial proteins, including
peptides derived from Staphylococcus aureus. This opens
the possibility that infection with S. aureus underlies the
development of PR3-ANCA, as discussed further subse-
quently. More recently, this group described T cells in the
peripheral blood of patients with PR3-ANCA AAV reacting
with cPR3 [30].
The second interesting observation was recently pub-
lished by Kain et al. [31￿]. In 1995, they described a novel
class of ANCA directed to the lysosomal membrane
glycoprotein hLAMP-2 [32]. This antigen is present not
only on the membrane of neutrophil granules but also on
other cells, such as endothelial cells. They observed that 78
of 84 (93%) patients with active ANCA-associated NCGN
had detectable anti–hLAMP-2 antibodies in their sera,
whereas only 6 of 84 (7%) were positive during remission.
The antibodies were not detectable in healthy controls or
diseased controls. To show the pathogenic potential of anti–
hLAMP-2, they raised anti–hLAMP-2 IgG class antibodies
in rabbits and injected these antibodies into rats. Rats
developed pauci-immune focal necrotizing glomerulone-
phritis. To explain the pathogenicity of anti–hLAMP-2,
they further showed that in vitro, the antibodies were able
to activate neutrophils and to kill human microvascular
endothelial cells. Most interestingly, they found that eight
of nine amino acids of the immunodominant epitope of
hLAMP-2 are identical to the P72-80 peptide of FimH, an
adhesion molecule of fimbriae from gram-negative bacteria.
Next, they immunized rats with FimH, which resulted in
antibodies cross-reacting with hLAMP-2, which in turn
induced pauci-immune glomerulonephritis. These data,
which still need to be confirmed by others, strongly suggest
a pathogenic role for anti–hLAMP-2 [33].
Taken together, in vivo experimental studies support, if
not prove, that MPO-ANCAs are pathogenic for necrotizing
vasculitis/glomerulonephritis. This is not as clear for PR3-
ANCAs. A pathogenic role for anti–hLAMP-2 antibodies
has been strongly suggested but awaits further study.
Besides Autoantibodies, is Cellular Immunity Involved
in the Pathogenesis of ANCA-Associated Vasculitis?
As mentioned, granulomatous inflammation is present in WG
associated with PR3-ANCA. In persisting localized WG,
ANCAs are not detectable in about 50% of patients [34]. This
suggests involvement of cellular immune effector mecha-
nisms. Indeed, Abdulahad et al. [35] described increased
levels of effector memory T cells in the peripheral blood of
patients with WG during remission. Immune effector cells
have been observed in granulomatous tissue in patients with
AAV [36]. Surprisingly, effector memory cells disappeared
from the peripheral blood during active disease in AAV.
Interestingly, however, these cells could be detected in the
urine during active disease with renal involvement [37￿].
These data suggest that even during remission, the immune
system is activated in patients with WG, and that these
activated cells migrate to the target organs during active
disease. The phenotype and cytokine pattern of the effector
memory cells in WG have been further defined. Both CD8
+
and CD4
+ T cells are present, but CD4
+ T cells producing
interleukin (IL)-17 seem to be more prominent. Analysis of
the intracellular cytokine pattern of peripheral blood cells
stimulated with the autoantigen PR3 in WG showed that the
(CD4
+) T cells proliferating upon interaction with PR3
produced—in the vast majority—IL-17 [38]. Indeed,
Nogueira et al. [39] reported elevated levels of IL-17 and
IL-23, as well as autoantigen-specific T-helper type 17
(Th17) cells in the peripheral blood of AAV patients. In an
animal model of anti-MPO glomerulonephritis, Gan et al.
[40￿] found that Th17 cells were instrumental in orchestrat-
ing renal injury. Thus, T-effector cells, in particular Th17
cells, seem to play a major role in the pathogenesis of AAVs.
Whereas most of the studies mentioned relate to the CD4
+
subset of T cells, a recent study described a transcription
signature of CD8
+ T cells that predicts poor prognosis in
patients with AAVs and systemic lupus erythematosus
(SLE). McKinney et al. [41￿] found that genes involved in
the IL-7 receptor pathway and T-cell–receptor signalling and
genes expressed by memory T cells were enriched in the
CD8
+ subset of patients with AAVs and SLE with a poor
prognosis. These data also point to a major role for Tcells in
the pathogenesis of AAVs. A hypothetical scheme of T-cell
involvement in AAV is shown in Fig. 1.
How are humoral and cellular responses in AAVs
regulated? Increasing attention has been paid to T-regulatory
cells (Tregs) in controlling autoimmunity. The phenotypic
and functional characterization of Tregs is still being
discussed. Abdulahad et al. [42] showed that CD4
+ Tcells
highly expressing CD25 on their surface—considered to
be natural Tregs—were increased in the peripheral blood
of AAV patients; however, their capacity to suppress
responses of CD25
- CD4
+ effector cells was highly
deficient. Functional impairment of Tregs in patients with
WG was also described by others [43]. Thus, deficient
function of Tregs may at least in part underlie the
autoimmune response in AAVs.
Role of Microbes in the Pathogenesis of AAVs
The etiology of AAVs is still unknown. Genetic factors
have been suggested but are not particularly strong [44].
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the etiology of AAVs. With respect to extrinsic factors,
toxic materials—in particular silica exposure—have been
incriminated [45]. More attention has been given to
microbial factors. Stegeman et al. [6] first noted that 63%
of patients with WG were chronic nasal carriers of S.
aureus and that S. aureus carriage was associated with a
higher relapse rate, with an adjusted relative risk of 7.16.
Furthermore, they showed that prophylactic treatment with
cotrimoxazole could prevent the occurrence of relapse
(60% reduction) [46]. The mechanisms underlying the
relationship between S. aureus and AAVs have not been
fully elucidated, but superantigen stimulation of B and T
cells and neutrophil activation have been proposed [47]. As
mentioned previously, Pendergraft et al. [29] presented
evidence that complementary PR3, which shows homology
with certain S. aureus–derived peptides, may induce anti-
bodies to PR3. As such, S. aureus carriage may, by
molecular mimicry, lead to the development of PR3-
ANCA. More studies are needed, however, to elucidate
how S. aureus carriage relates mechanistically to AAVs.
A recent study also points to the role of microbes in the
etiopathogenesis of AAVs. As mentioned previously, Kain
et al. [31￿] described autoantibodies to hLAMP-2 as a
sensitive and specific marker for ANCA-associated pauci-
immune glomerulonephritis. They also showed cross-
reactivity between an immunodominant epitope of
hLAMP-2 and FimH. Immunization of rats with FimH
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Fig 1 A proposed model representing innate and adaptive immune
mechanisms supposedly involved in the pathogenesis of antineutrophil
cytoplasmic autoantibody (ANCA)-associated systemic vasculitis.
Superantigens and peptidoglycans from Staphylococcus aureus stim-
ulate antigen-presenting cells (APCs) in the respiratory tract to
produce interleukin (IL)-23, which then induces proliferation of T-
helper (Th) type 17 cells and release of IL-17. IL-17 acts further on
respiratory epithelium and tissue macrophages. In response to IL-17,
bronchial epithelial cells secrete CXC chemokines that attract
neutrophils to the infected tissue, whereas macrophages release
proinflammatory cytokines such as IL-1β and tumor necrosis factor
(TNF)-α. These inflammatory cytokines cause priming of neutrophils
(membrane expression of proteinase 3 [PR3]) and upregulation of
adhesion molecules on their surface as well as on the vascular
endothelium. Subsequently, primed neutrophils adhere to the endo-
thelial cells. Released PR3 can be processed and presented by APCs to
Th cells. As T-regulatory cells (Tregs) fail to inhibit this autoimmune
response in Wegener’s granulomatosis, autoreactive T cells might
undergo repeated stimulation by PR3-pulsed APCs, resulting in a pool
of effector memory T cells (TEMs). Furthermore, PR3-stimulated Th
cells act on B cells and enhance the production of ANCAs.
Subsequently, ANCAs activate neutrophils that adhere to endothelial
cells, resulting in local production of reactive oxygen species (ROS)
and release of proteolytic enzymes that damage vascular endothelial
cells. Moreover, the expanded population of CD4
+ TEMs resulting
from persistent activation of Th cells by PR3 upregulate their NKG2D
protein and migrate to the peripheral blood and remain in the
circulation during remission. When the disease becomes active, MICA
protein will be upregulated on several vascular endothelial cells
(especially in the kidney), which attract TEMs to the inflammatory
areas. The MICA protein on the target cells can bind to NKG2D on
the TEMs, which in turn enhances their cytotoxic function to kill the
target cell in a perforin- and granzyme-dependent way, ending up in
vasculitis. (From Abdulahad et al. [48]; with permission.)
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antibodies to hLAMP-2 and pauci-immune glomerulone-
phritis. Furthermore, they noticed in a small group of
patients that most had acquired an infection with gram-
negative bacteria before the onset of AAV (accompanied by
hLAMP-2 antibodies). These data, which must be extended
and confirmed, suggest that infection with gram-negative
bacteria may lead, in a susceptible individual, to the
development of AAVs.
Conclusions
The close association between AAVand PR3-ANCA/MPO-
ANCA suggests that the autoantibodies are involved in the
pathogenesis of these diseases. Clinical data support, but
certainly do not prove, this suggestion. In vitro experimen-
tal data point to the pathogenetic pathways involved in
lesion development, in which, in addition to the autoanti-
bodies, neutrophils, the alternative pathway of the comple-
ment system, and endothelial cells play a major role. In
vivo experimental studies strongly support a pathogenic
role for MPO-ANCA, but an animal model for PR3-ANCA
is lacking. In PR3-ANCA–associated WG, T cells seem to
play a major role as well. Finally, microbial factors seem to
be involved in disease induction and possibly in disease
expression. Although great progress has been made in the
understanding of AAVs, further studies are needed to fully
elucidate the etiopathogenesis of these diseases.
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